Cigna cuts employee drug benefits
Cigna halts GLP-1 obesity drug coverage for its employees starting July 1
Cigna will stop covering GLP-1 weight-loss drugs for its own employees starting July 1, the health insurer confirmed this week. The change affects roughly 67,700 workers and cuts off insurance coverage for drugs like Wegovy and Zepbound, according to Reuters.
Cigna sent an internal email to staff on June 1 announcing the move. Employees who currently use the drugs can still get them — but they will have to pay cash, through manufacturer websites or the federal TrumpRx platform. Coverage for type 2 diabetes treatment is not affected, according to Crossroads Today.
Cigna Cites Costs That Became Unsustainable
GLP-1 drugs like Wegovy and Zepbound cost employers a lot. Between 2024 and 2025, Cigna's pharmacy unit saw a 40–50% surge in annual costs tied to these medications. By 2025, nearly 80% of U.S. employers said GLP-1s were the top driver of rising health costs, according to a Business Group on Health survey cited by Tulsa World.
A Cigna spokesperson told Becker's Payer Issues the change was needed to keep benefits "sustainable" and "aligned with the unique needs of our workforce." Analysts say the cut could improve Cigna's medical cost ratio by 50–80 basis points in the next fiscal year.
TrumpRx Gave Cigna a Way Out
The decision lines up with a major shift in how these drugs are sold. In February 2026, the Trump administration launched TrumpRx.gov, a direct-to-consumer platform offering GLP-1s at sharply reduced cash prices. Wegovy pens run $199 per month. Zepbound costs $299 per month. That is far below the old retail price of $1,350, according to Billings Gazette.
Cigna's email pointed employees toward TrumpRx and drug manufacturer sites as alternatives. The White House views Cigna's move as a sign the program is working. From their perspective, the goal was to make drugs affordable enough that workers would not need insurance to access them.
Employees Face Higher Bills Starting July 1
Before July 1, many Cigna employees paid a $20–$50 co-pay for these drugs. After the change, they will pay $149 to $299 per month out of pocket. That money will not count toward their insurance deductible, according to Reuters. June 30 is the last day employees can get a refill under the old coverage.
Reaction inside the company has been sharp. On Reddit, Cigna employees called the news "devastating." The Obesity Action Coalition pushed back publicly, arguing that cutting coverage treats obesity as a cosmetic problem rather than the chronic disease it is. They said shifting workers to a cash-pay model "places the burden of health entirely onto the individual."
A Ripple Effect Across Corporate America
Cigna is not just an employer — it designs health plans for millions of other workers. Analysts say its own coverage cut sends a clear signal to its clients. If the insurer won't cover GLP-1s for its own staff, smaller companies are likely to follow, according to NWI Times.
Cigna's move also comes after a legal win. In February 2026, the U.S. Court of Appeals for the First Circuit ruled that excluding weight-loss drugs did not violate the Affordable Care Act. That ruling cleared the way for broader employer retreats from GLP-1 coverage across the industry, according to Pantagraph.
Sentiment
NeutralPublishers
18
Articles
17
Reach
18
